Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

OJOmer JamyMEManuel Espinoza-GutarraRBRavi Bhatia

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows acute myeloid leukemia patients achieve improved responses with safety profile in real-world setting.

Key Points

  • Best overall response rate reached 63% and complete remission rate was 53% in patients with acute myeloid leukemia.
  • Median overall survival was reported at 8.44 months with notable results in adverse-risk subgroups.
  • Reduced venetoclax duration of 10 days was combined with decitabine in a real-world observational analysis.
  • The study supports the feasibility of a shorter regimen with lower infection rates in elderly patients.

Cite This Study

Jamy et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3c3https://doi.org/10.1182/blood-2025-1668
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  2. 2Dose-adjusted treatment with venetoclax for 7 days and 5-azacitidine or decitabine in patients with Acute Myeloid Leukemia or higher risk myelodysplastic neoplasms2025
  3. 3Real-world experience with front-line metronomic low-dose weekly decitabine and venetoclax in elderly and/or frail patients with MDS or AML2025
  4. 4Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  5. 5Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study2025